4//SEC Filing
Saad Mark E 4
Accession 0001193125-26-001181
CIK 0001579428other
Filed
Jan 1, 7:00 PM ET
Accepted
Jan 2, 7:02 PM ET
Size
14.7 KB
Accession
0001193125-26-001181
Insider Transaction Report
Form 4
Saad Mark E
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-31$8.02/sh+6,231$49,973→ 16,233 total - Sale
Common Stock
2025-12-31$165.18/sh−6,231$1,029,237→ 10,002 total - Exercise/Conversion
Common Stock
2025-12-31$4.95/sh+31,346$155,163→ 41,348 total - Sale
Common Stock
2025-12-31$165.18/sh−31,346$5,177,732→ 10,002 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-31−6,231→ 0 totalExercise: $8.02From: 2017-05-27Exp: 2026-05-27→ Common Stock (6,231 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-31−31,346→ 0 totalExercise: $4.95From: 2018-03-15Exp: 2027-03-15→ Common Stock (31,346 underlying)
Holdings
- 300(indirect: See explanation 5 below.)
Common Stock
Footnotes (5)
- [F1]Represents an exercise of stock options prior to the 10-year expiration date of such options.
- [F2]Such transaction was pursuant to a pre-approved 10b5-1 plan.
- [F3]Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- [F4]Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $165.00 and $166.09.
- [F5]Represents additional shares held indirectly by the Reporting Person prior to December 31, 2025 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.
Documents
Issuer
Axsome Therapeutics, Inc.
CIK 0001579428
Entity typeother
Related Parties
1- filerCIK 0001295913
Filing Metadata
- Form type
- 4
- Filed
- Jan 1, 7:00 PM ET
- Accepted
- Jan 2, 7:02 PM ET
- Size
- 14.7 KB